Legislators
Bills
Statements
Lobbying
Travel
Searching...- Bills
- H.RES.161
H.RES.161: Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
About This Bill
- This bill was introduced in the 113th Congress
- This bill is primarily about health
- Introduced April 15, 2013
- Latest Major Action April 19, 2013
Bill Sponsor
Bill Cosponsors
7 (4 Democrats, 3 Republicans)
Bill Summary
Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.
(Source: Library of Congress)
Bill Actions
| Date | Description |
|---|---|
| April 19, 2013 |
Referred to the Subcommittee on Health.
|
| April 15, 2013 |
Referred to the House Committee on Energy and Commerce.
|
| April 15, 2013 |
Introduced in the House by Harold Rogers (R-Ky.) |